Skip to content

EV / sales at other companies

Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.9×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
10.7×-12.1×
ALN
Alnylam PharmaceuticalsALNY
9.9×-4.7×
Beam Therapeutics logo
Beam TherapeuticsBEAM
14.6×-10.3×

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.11B+9.2%
Enterprise value$577.44M-27.2%
P/S14.6×-11.8×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

Based on the most recent quarter.

The official record: Wave Life Sciences’s 10-Q, filed August 8, 2024, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's EV / sales?
Wave Life Sciences (WVE) reported EV / sales of 4.7× in Q2 2024.
How has Wave Life Sciences's EV / sales changed year-over-year?
Wave Life Sciences's EV / sales decreased by 30.7% year-over-year, from 6.8× to 4.7×.
What is the long-term trend for Wave Life Sciences's EV / sales?
Over 3 years (2020 to 2023), Wave Life Sciences's EV / sales has grown at a -39.5% compound annual growth rate (CAGR), from 15.3× to 3.4×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.